Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 2
1969 1
1972 2
1973 3
1974 2
1975 1
1977 1
1979 2
1980 5
1981 2
1982 3
1983 3
1984 6
1985 5
1986 5
1987 5
1988 4
1989 5
1990 7
1991 11
1992 10
1993 12
1994 17
1995 21
1996 10
1997 12
1998 14
1999 17
2000 17
2001 21
2002 28
2003 15
2004 13
2005 15
2006 19
2007 14
2008 19
2009 25
2010 18
2011 13
2012 20
2013 20
2014 20
2015 39
2016 19
2017 29
2018 22
2019 14
2020 30
2021 30
2022 32
2023 32
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

660 results

Results by year

Filters applied: . Clear all
Page 1
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. We assessed the efficacy and safe …
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unc …
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies.
Walsh R, Offerhaus JA, Tadros R, Bezzina CR. Walsh R, et al. Nat Rev Cardiol. 2022 Mar;19(3):151-167. doi: 10.1038/s41569-021-00608-2. Epub 2021 Sep 15. Nat Rev Cardiol. 2022. PMID: 34526680 Review.
Hypertrophic cardiomyopathy (HCM) was traditionally described as an autosomal dominant Mendelian disease but is now increasingly recognized as having a complex genetic aetiology. ...Genes associated with Mendelian cardiomyopathy are enriched in the putative c …
Hypertrophic cardiomyopathy (HCM) was traditionally described as an autosomal dominant Mendelian disease but is now increasing …
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Braunwald E, et al. Eur Heart J. 2023 Nov 21;44(44):4622-4633. doi: 10.1093/eurheartj/ehad637. Eur Heart J. 2023. PMID: 37804245 Free PMC article. Review.
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mav …
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatmen …
[Hypertrophic cardiomyopathy].
Batzner A, Seggewiß H. Batzner A, et al. Herz. 2020 May;45(3):233-242. doi: 10.1007/s00059-020-04899-y. Herz. 2020. PMID: 32185419 Review. German.
Hypertrophic cardiomyopathy is the most common genetically determined cardiac disease with a prevalence of 0.2-0.6%. ...
Hypertrophic cardiomyopathy is the most common genetically determined cardiac disease with a prevalence of 0.2-0.6%. ...
Hypertrophic cardiomyopathy: a review.
Hensley N, Dietrich J, Nyhan D, Mitter N, Yee MS, Brady M. Hensley N, et al. Anesth Analg. 2015 Mar;120(3):554-569. doi: 10.1213/ANE.0000000000000538. Anesth Analg. 2015. PMID: 25695573 Review.
Hypertrophic cardiomyopathy (HCM) is a relatively common disorder that anesthesiologists encounter among patients in the perioperative period. ...Cardiac magnetic resonance imaging also has a diagnostic role by determining the extent and location of left ventricular …
Hypertrophic cardiomyopathy (HCM) is a relatively common disorder that anesthesiologists encounter among patients in the perio …
Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature.
Bayonas-Ruiz A, Muñoz-Franco FM, Sabater-Molina M, Oliva-Sandoval MJ, Gimeno JR, Bonacasa B. Bayonas-Ruiz A, et al. ESC Heart Fail. 2023 Feb;10(1):8-23. doi: 10.1002/ehf2.14142. Epub 2022 Oct 1. ESC Heart Fail. 2023. PMID: 36181355 Free PMC article. Review.
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical characteristics of patients with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: A systematic review and meta-analysis …
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical c …
Considerations for specific cardiomyopathies during pregnancy.
Abrams M, Magun E, DeFilippis EM. Abrams M, et al. Curr Opin Cardiol. 2023 May 1;38(3):233-240. doi: 10.1097/HCO.0000000000001033. Epub 2023 Mar 1. Curr Opin Cardiol. 2023. PMID: 37016994 Review.
The goal of this review is to summarize current knowledge on various cardiomyopathies in pregnancy, with an emphasis on cardiomyopathies beyond the most common in pregnancy, peripartum cardiomyopathy. RECENT FINDINGS: Although existing literature is somewhat limited, outco …
The goal of this review is to summarize current knowledge on various cardiomyopathies in pregnancy, with an emphasis on cardiomyopathies bey …
Novel Therapeutic Avenues for Hypertrophic Cardiomyopathy.
Patil D, Bhatt LK. Patil D, et al. Am J Cardiovasc Drugs. 2023 Nov;23(6):623-640. doi: 10.1007/s40256-023-00609-1. Epub 2023 Sep 5. Am J Cardiovasc Drugs. 2023. PMID: 37670168 Review.
Hypertrophic cardiomyopathy (HCM) is a complicated, heterogeneous genetic condition that causes left ventricular hypertrophy, fibrosis, hypercontractility, and decreased compliance. Despite the advances made over the past 3 decades in understanding the molecu …
Hypertrophic cardiomyopathy (HCM) is a complicated, heterogeneous genetic condition that causes left ventricular hypertrophy, …
Mavacamten-A Targeted Therapy for Hypertrophic Cardiomyopathy.
Schenk A, Fields N. Schenk A, et al. J Cardiovasc Pharmacol. 2023 May 1;81(5):317-326. doi: 10.1097/FJC.0000000000001416. J Cardiovasc Pharmacol. 2023. PMID: 36878205 Review.
The pathophysiology of hypertrophic cardiomyopathy is primarily comprised of dynamic left ventricular outflow tract obstruction, mitral regurgitation, and diastolic dysfunction. ...Mavacamten is a novel cardiac myosin inhibitor recently approved by the Food and Drug …
The pathophysiology of hypertrophic cardiomyopathy is primarily comprised of dynamic left ventricular outflow tract obstructio …
Leopard syndrome.
Sarkozy A, Digilio MC, Dallapiccola B. Sarkozy A, et al. Orphanet J Rare Dis. 2008 May 27;3:13. doi: 10.1186/1750-1172-3-13. Orphanet J Rare Dis. 2008. PMID: 18505544 Free PMC article. Review.
Stature is usually below the 25th centile. Cardiac defects, in particular hypertrophic cardiomyopathy mostly involving the left ventricle, and ECG anomalies are common. ...Clinical management should address growth and motor development and congenital anomalies, in p …
Stature is usually below the 25th centile. Cardiac defects, in particular hypertrophic cardiomyopathy mostly involving the lef …
660 results